| Study ID |
PI |
Description |
Contact Information |
| NCT02336217 |
Dr. Henry Driscoll |
Glycemic Emergency Management (GEM); An App for Rapid Response to Hypogycemic and Hyperglycemic Situations (GEMApp) |
Dr. Henry Driscoll |
| NCT03537508 |
Dr. Jessie Shields |
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US (MET 42 SANOFI) |
Gina Finley, PharmD |
| NCT03012776 |
Dr. Nicolas Phan |
A Pivotal Study of the Premia Spine TOPS System (TOPS IDE) |
Jessica Merrick, RN |
| NCT06063967 |
Dr. Umapathy Sundaram |
AFFIRM – Crohn’s Disease: Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn’s Disease |
Nicole Finley, MSN, RN, ACCNS-AG |
| NCT06589986 |
Dr. Umapathy Sundaram |
AMETRINE-1; A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy with RO7790121 in Patients with Moderately to Severely Active Ulcerative Colitis (GA45329) |
Nicole Finley, MSN, RN, ACCNS-AG |
| NCT06388421 |
Dr. Amro Al-Astal |
DeciPHer-ILD (GMS-PH-401): A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) |
Amber Vickers, RN |
| NCT06257875 |
Dr. Umapathy Sundaram |
HORIZON: A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis |
Nicole Finley, MSN, RN, ACCNS-AG |
| NCT05686070 |
Dr. Jorge Lopez |
OCEANIC STROKE – A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA |
Gina Finley, PharmD
Amber Vickers, RN |
| NCT04396236 |
Dr. Jorge Lopez |
PIONEER-PEDS1: Protocol H8H-MC-LAHV(a) Pediatric Options for Migraine Relief: A Randomized, Double-Blind, Placebo-Controlled Study of Lasmiditan for Acute Treatment of Migraine |
Amber Vickers, RN |
| NCT04396574 |
Dr. Jorge Lopez |
PIONEER-PEDS2: Protocol H8H-MC-LAHW A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine |
Amber Vickers, RN |
| NCT04965675 |
Dr. Jorge Lopez |
PROSPECT II – Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of IV eptinezumab in adolescents (12-17 years) for the preventive treatment of chronic migraine |
Jessica Merrick, RN |
| NCT05643534 |
Dr. Xavier Villa |
RALLY – (Ten-01-304) A 12 week, Randomized, Double blind, placebo controlled, phase 3 study to assess the safety and efficacy of a Tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) in pediatric patients 12 to less than 18 years old |
Jessica Merrick, RN |
| NCT06553547 |
Dr. Xavier Villa |
RALLY 202: (Ten-01-202) A 4-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Tenapanor for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Pediatric Patients 6 to Less than 12 Years Old |
Jessica Merrick, RN |
| NCT05905926 |
Dr. Xavier Villa |
Rall-Y 306: TEN-01-306 An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Pediatric Patients 6 to Less than 18 Years Old |
Jessica Merrick, RN |
| NCT05889624 |
Dr. Jorge Lopez |
REACH – Responding with Evidence and Access for Childhood Headaches: The REACH Study |
Hillary Salava, RN |
| NCT04753385 |
Dr. Suzanne Holroyd |
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy® System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression |
Hillary Salava, RN |
| NCT06305780 |
Dr. Imran Khawaja |
RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) |
Jessica Merrick, RN
Nicole Finley, MSN, RN, ACCNS-AG |
| NCT06404047 |
Dr. Imran Khawaja |
RECOVER-ENERGIZE: A Platform Protocol for Evaluation of Interventions for Exercise Intolerance in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) |
Hillary Salava, RN
Nicole Finley, MSN, RN, ACCNS-AG |
| NCT06404086 |
Dr. Imran Khawaja |
RECOVER – Sleep: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) |
Gina Finley, PharmD
Nicole Finley, MSN, RN, ACCNS-AG |
| NCT04748601 |
Dr. Jorge Lopez |
ROAR – A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 4 Study to Evaluate the Efficacy and Safety of Qudexy® XR in the Prevention of Migraine in Children 6 to 11 Years of Age |
Amber Vickers, RN |
| NCT06819891 |
Dr. Umapathy Sundaram |
SIBERITE-2 (GA45332): A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Access the Efficacy and Safety of Induction Therapy with RO7790121 in Patient with Moderately to Severely Active Crohn’s Disease |
Nicole Finley, MSN, RN, ACCNS-AG |
| NCT06625060 |
Dr. Jorge Lopez |
MERANTI- A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults |
Nicole Finley, MSN, RN, ACCNS-AG |
